BioCentury
ARTICLE | Clinical News

Iomab-B: Phase II data

December 10, 2012 8:00 AM UTC

A Phase II trial in 14 patients <50 years old with advanced AML or high-risk MDS showed that Iomab-B plus fludarabine and total body irradiation given before myeloablative HCT led to a PFS rate of 36%...